AU2016246524B2 - Pharmaceutical compositions for combination therapy - Google Patents

Pharmaceutical compositions for combination therapy Download PDF

Info

Publication number
AU2016246524B2
AU2016246524B2 AU2016246524A AU2016246524A AU2016246524B2 AU 2016246524 B2 AU2016246524 B2 AU 2016246524B2 AU 2016246524 A AU2016246524 A AU 2016246524A AU 2016246524 A AU2016246524 A AU 2016246524A AU 2016246524 B2 AU2016246524 B2 AU 2016246524B2
Authority
AU
Australia
Prior art keywords
insulin
pharmaceutical composition
liver
disease
oca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016246524A
Other languages
English (en)
Other versions
AU2016246524A1 (en
Inventor
Luciano Adorini
Mark Pruzanski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercept Pharmaceuticals Inc
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of AU2016246524A1 publication Critical patent/AU2016246524A1/en
Application granted granted Critical
Publication of AU2016246524B2 publication Critical patent/AU2016246524B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016246524A 2015-04-07 2016-04-06 Pharmaceutical compositions for combination therapy Ceased AU2016246524B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144040P 2015-04-07 2015-04-07
US62/144,040 2015-04-07
PCT/US2016/026146 WO2016164413A1 (en) 2015-04-07 2016-04-06 Pharmaceutical compositions for combination therapy

Publications (2)

Publication Number Publication Date
AU2016246524A1 AU2016246524A1 (en) 2017-10-26
AU2016246524B2 true AU2016246524B2 (en) 2021-04-01

Family

ID=57072872

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016246524A Ceased AU2016246524B2 (en) 2015-04-07 2016-04-06 Pharmaceutical compositions for combination therapy

Country Status (25)

Country Link
US (1) US10894054B2 (enExample)
EP (1) EP3280421B1 (enExample)
JP (1) JP6879931B2 (enExample)
KR (1) KR20170132879A (enExample)
CN (1) CN107613986A (enExample)
AR (1) AR104195A1 (enExample)
AU (1) AU2016246524B2 (enExample)
BR (1) BR112017021311A2 (enExample)
CA (1) CA2981507A1 (enExample)
CL (2) CL2017002538A1 (enExample)
CO (1) CO2017010292A2 (enExample)
CR (1) CR20170456A (enExample)
EA (1) EA036757B1 (enExample)
EC (1) ECSP17073004A (enExample)
ES (1) ES2974281T3 (enExample)
IL (2) IL254772A0 (enExample)
MA (1) MA41083A1 (enExample)
MX (1) MX2017012893A (enExample)
NI (1) NI201700121A (enExample)
PE (1) PE20180034A1 (enExample)
SM (1) SMT202400104T1 (enExample)
SV (1) SV2017005539A (enExample)
TN (1) TN2017000426A1 (enExample)
TW (1) TW201642869A (enExample)
WO (1) WO2016164413A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
JP6687544B2 (ja) 2014-05-28 2020-04-22 チルドレンズ ホスピタル メディカル センター 前駆細胞を指向性分化によって胃組織に変換するための方法及びシステム
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
MX386778B (es) 2015-03-09 2025-03-19 Intekrin Therapeutics Inc Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia.
WO2017182873A2 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
SG11201903697WA (en) 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
NZ753873A (en) 2016-12-05 2023-01-27 Children’S Hospital Medical Center Colonic organoids and methods of making and using same
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
JP2020536529A (ja) 2017-10-10 2020-12-17 チルドレンズ ホスピタル メディカル センター 食道組織および／または臓器組成物およびそれを作製する方法
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
US10806735B2 (en) * 2018-04-24 2020-10-20 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
AU2019339410A1 (en) 2018-09-12 2021-04-15 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
EP3866776A4 (en) * 2018-10-18 2022-08-10 Avolynt USE OF SGLT2 INHIBITORS TO TREAT PRIMARY SCLEROSING CHOLANGITIS
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
WO2020108830A1 (en) * 2018-11-30 2020-06-04 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
CN113874023A (zh) * 2019-03-26 2021-12-31 英特塞普特医药品公司 使用奥贝胆酸诊断和治疗肝病的方法
US20220288054A1 (en) * 2019-04-04 2022-09-15 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
JP7610533B2 (ja) 2019-05-31 2025-01-08 チルドレンズ ホスピタル メディカル センター 造血幹細胞の生成および拡大方法
WO2021029656A1 (ko) * 2019-08-14 2021-02-18 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
JP2024503861A (ja) * 2021-01-14 2024-01-29 ウエヌイグレックオ・ファーマ 慢性腎疾患を処置する方法
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
JP2025517334A (ja) 2022-05-16 2025-06-05 スパロー ファーマシューティカルズ，インコーポレーテッド グルココルチコイド過剰を治療するための方法及び組成物
JP2025519533A (ja) * 2022-06-08 2025-06-26 コージン セラピューティクス， インコーポレイテッド 体重減少を開始させる、調節する、およびモジュレートするための方法および組成物、ならびにその治療的適用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044391A1 (en) * 2004-10-14 2006-04-27 Intercept Pharmaceuticals Inc. A method of reducing drug-induced adverse side effects in a patient
US20090312246A1 (en) * 2005-08-19 2009-12-17 Amylin Pharmaceuticals, Inc. Uses of Glucoregulatory Proteins

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
ES2326850T3 (es) 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
WO2000040965A1 (en) 1999-01-07 2000-07-13 Tularik, Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
MXPA01009814A (es) 1999-03-29 2002-04-24 Hoffmann La Roche Activadores de la glucoquinasa.
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
CA2549015A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic c-glycosides
EA010655B1 (ru) 2003-08-01 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индазол-о-глюкозиды
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
SI2712617T1 (sl) 2004-03-12 2017-01-31 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo Fxr ligandov
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
PL2347762T3 (pl) 2005-08-19 2019-09-30 Amylin Pharmaceuticals, Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
ATE526318T1 (de) * 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
DK2029547T3 (da) 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
EP2029558B1 (en) 2006-05-24 2010-03-10 Eli Lilly And Company Compounds and methods for modulating fxr
EP2040713B1 (en) 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
AU2007333194A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. LXR and FXR modulators
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
US20100056546A1 (en) 2008-09-04 2010-03-04 Auspex Pharmaceuticals, Inc. Sulfonylurea inhibitors of atp-sensitive potassium channels
JP2012528170A (ja) 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2539389B1 (en) 2010-02-24 2017-12-20 Relypsa, Inc. Amine polymers for use as bile acid sequestrants
US9775556B2 (en) 2010-05-26 2017-10-03 Andre′ A. DiMino Apparatus and method for uroflowmetry
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
EP2617514A4 (en) 2010-09-15 2018-01-03 Sumitomo Electric Industries, Ltd. Laser processing method
WO2012106581A1 (en) 2011-02-03 2012-08-09 The University Of Chicago Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction
CA2877122C (en) 2012-06-19 2020-04-28 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
EP2997035B8 (en) 2013-05-14 2018-05-23 Intercept Pharmaceuticals, Inc. 11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
CN107405325B (zh) * 2015-02-06 2021-11-12 英特塞普特医药品公司 用于组合疗法的药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044391A1 (en) * 2004-10-14 2006-04-27 Intercept Pharmaceuticals Inc. A method of reducing drug-induced adverse side effects in a patient
US20090312246A1 (en) * 2005-08-19 2009-12-17 Amylin Pharmaceuticals, Inc. Uses of Glucoregulatory Proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIAOKUN DING ET AL, "Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis inob/ob mice", HEPATOLOGY, (2006-01-01), vol. 43, no. 1, doi:10.1002/hep.21006, ISSN 0270-9139, pages 173 - 181 *

Also Published As

Publication number Publication date
CL2018001007A1 (es) 2018-06-15
US20180117065A1 (en) 2018-05-03
MA41083A1 (fr) 2018-05-31
PE20180034A1 (es) 2018-01-09
KR20170132879A (ko) 2017-12-04
EP3280421B1 (en) 2023-12-27
TN2017000426A1 (en) 2019-04-12
EP3280421A1 (en) 2018-02-14
SV2017005539A (es) 2019-01-18
IL268316A (en) 2019-09-26
WO2016164413A1 (en) 2016-10-13
CA2981507A1 (en) 2016-10-13
ES2974281T3 (es) 2024-06-26
CO2017010292A2 (es) 2018-01-05
BR112017021311A2 (pt) 2018-06-26
AU2016246524A1 (en) 2017-10-26
NI201700121A (es) 2018-01-10
MX2017012893A (es) 2018-01-15
JP6879931B2 (ja) 2021-06-02
ECSP17073004A (es) 2018-02-28
SMT202400104T1 (it) 2024-05-14
CR20170456A (es) 2018-06-13
EA036757B1 (ru) 2020-12-17
AR104195A1 (es) 2017-07-05
CL2017002538A1 (es) 2018-04-20
JP2018510900A (ja) 2018-04-19
IL268316B (en) 2022-02-01
EP3280421A4 (en) 2019-08-28
TW201642869A (zh) 2016-12-16
CN107613986A (zh) 2018-01-19
US10894054B2 (en) 2021-01-19
IL254772A0 (en) 2017-12-31
EA201792203A1 (ru) 2018-02-28

Similar Documents

Publication Publication Date Title
AU2016246524B2 (en) Pharmaceutical compositions for combination therapy
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
Lan et al. L-arginine ameliorates lipopolysaccharide-induced intestinal inflammation through inhibiting the TLR4/NF-κB and MAPK pathways and stimulating β-defensin expression in vivo and in vitro
Yang et al. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation
Jung et al. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy
Diao et al. Potential therapeutic activity of berberine in thyroid-associated ophthalmopathy: inhibitory effects on tissue remodeling in orbital fibroblasts
US20240066020A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
Tahara Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH
Liu et al. G-Rh4 improves pancreatic β-cells dysfunction in vivo and in vitro by increased expression of Nrf2 and its target genes
Lu et al. A bovine milk-derived peptide ameliorates pancreatic β-cell dedifferentiation through PI3K/Akt/FOXO1 signaling in type 2 diabetes
RU2727142C2 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
Ke et al. Gliquidone decreases urinary protein by promoting tubular reabsorption in diabetic Goto-Kakizaki rats
Yu et al. Atractylodin alleviates cancer anorexia-cachexia syndrome by regulating NPY through hypothalamic Sirt1/AMPK axis-induced autophagy
Li et al. Proteoglycan extracted from Ganoderma lucidum ameliorated diabetes-induced muscle atrophy via the AMPK/SIRT1 pathway in vivo and in vitro
US9446053B2 (en) Method for enhancing the secretion of GLP-1 using bitter compounds
HK1242970A1 (en) Pharmaceutical compositions for combination therapy
CN113855812B (zh) 聚乙二醇洛塞那肽或其药物组合物的新医药用途
EP4424317A1 (en) Medicine for preventing or treating enteritis and intestinal cancer
Hsu et al. Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway.
Wang et al. Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in mouse models of type 2 diabetes
Zhao The physiological role of Nrf2 in diabetic kidney disease
Lee et al. Isobavachalcone reduces blood glucose and promotes muscle development via dipeptidyl peptidase-4 inhibition
CN121154625A (zh) 5-甲氧基邪蒿素在制备用于预防和/或治疗胆汁淤积性肝病的药物中的应用
CN116570715A (zh) Derlin-1或其表达上调剂在制备防治非酒精性脂肪肝病药物中的应用
Sanchetee et al. Diabetes and Cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired